PD1/PDL1, CTLA-4, and LAG-3 are well-established inhibitory signaling axes in T cells in several cancers in animal models and patients, resulting in several FDA-approved therapies targeting these axes (immune checkpoint blockade; ICB). Here, LAG3 is linked to cancer.